.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

RELENZA Drug Profile

« Back to Dashboard
Relenza is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from three suppliers.

The generic ingredient in RELENZA is zanamivir. Three suppliers are listed for this compound. Additional details are available on the zanamivir profile page.

Summary for Tradename: RELENZA

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list3

Pharmacology for Tradename: RELENZA

Clinical Trials for: RELENZA

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline
RELENZA
zanamivir
POWDER;INHALATION021036-001Jul 26, 1999RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: RELENZA

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline
RELENZA
zanamivir
POWDER;INHALATION021036-001Jul 26, 19995,035,237<disabled>
Glaxosmithkline
RELENZA
zanamivir
POWDER;INHALATION021036-001Jul 26, 19994,627,432<disabled>
Glaxosmithkline
RELENZA
zanamivir
POWDER;INHALATION021036-001Jul 26, 19996,294,572<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc